ISRCTN95583524已完成未知
Mesothelioma And Radical Surgery
Guy's and St. Thomas' Hospitals NHS Foundation Trust (UK)0 个研究点目标入组 100 人开始时间: 2004年7月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
- 2006 protocol in http://www.ncbi.nlm.nih.gov/pubmed/17670513 2. 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19661833 3. 2011 results in http://www.ncbi.nlm.nih.gov/pubmed/21723781
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Two phase eligibility:
- •Registration Eligibility criteria at registration:
- •1. 18 years of age or older
- •2. Histologically proven mesothelioma
- •3. Fit to undergo extrapleural pneumonectomy (EPP) as per British Thoracic Society (BTS) guidelines
- •4. Fit to undergo the planned post-operative radiotherapy
- •5. Able to complete Quality of Life questionnaires
- •6. Able to comply with follow-up requirements
- •7. Written informed consent for registration
- •8. Positron emission tomography (PET) or mediastinoscopy negative
- •9. No distant metastases
- •Once chemotherapy has been completed a further eligibility criteria is checked to determine continued eligibility for randomisation.
- •Eligibility criteria for randomisation:
- •1. Still fulfil eligibility criteria for registration
- •2. Completion of 3 cycles of chemotherapy
- •3. Operable disease (T1-3, N0-1, M0)
- •4. Biopsy proven malignant mesothelioma on histology and immuno-histochemistry
- •5. Normal renal function
- •6. World Health Organisation (WHO) performance status 0 or 1
- •7. Written informed consent for randomisation
排除标准
- •1. Predicted post-operative forced expiratory volume in 1 second (FEV1) of less than 40% and carbon monoxide transfer factor (TLCO) of less than 40%
- •2. Significant pulmonary hypertension
- •3. Cardiac ejection fraction of less than 40%
研究者
相似试验
Unknown
不适用
Mesothelioma and Radical Surgery 2MesotheliomaNCT02040272Royal Brompton & Harefield NHS Foundation Trust328
进行中(未招募)
1 期
Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparib MiST 2 abemaciclib MiST 3 pembrolizumab in combination with bemcentinib MiST 4 atezolizumab in combination with bevacizumabMalignant Mesothelioma (MM) - pleural and peritonealEUCTR2017-003353-41-GBniversity of Leicester120
已完成
2 期
Tomotherapy Treatment for MesotheliomaMesotheliomaNCT00469196AHS Cancer Control Alberta18
尚未招募
2 期
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOtheliomaAdvanced Malignant Pleural or Peritoneal MesotheliomaNCT04462809Hospices Civils de Lyon40
Unknown
不适用
Trimodality Therapy for Malignant Pleural MesotheliomaMalignant Pleural MesotheliomaNCT01343264HSK Wiesbaden200
